The economic burden of drug resistance.
Clin Infect Dis
; 41 Suppl 4: S283-6, 2005 Aug 15.
Article
em En
| MEDLINE
| ID: mdl-16032567
ABSTRACT
In recent years, researchers have made substantial progress in the development of methods to measure the burden of resistance and the application of those methods to the limited data available. Our understanding of the costs incurred by patients infected with resistant strains in hospital settings is much better than it was 10, or even 5, years ago. Research on the impact of resistance in the community is more limited. When multiple treatment options are available and prescribed treatment is empirical, resistance will lead to higher expenditures on drugs but not necessarily to increased patient morbidity and mortality. Understanding to what degree prescribing patterns are driven by real versus perceived limitations of first-line drugs is important for assessing the ability of public health campaigns to change the behavior of patients and providers.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Resistência a Medicamentos
/
Doenças Transmissíveis
/
Controle de Infecções
/
Custos de Cuidados de Saúde
/
Efeitos Psicossociais da Doença
Tipo de estudo:
Health_economic_evaluation
Limite:
Humans
Idioma:
En
Revista:
Clin Infect Dis
Assunto da revista:
DOENCAS TRANSMISSIVEIS
Ano de publicação:
2005
Tipo de documento:
Article
País de afiliação:
Estados Unidos